small win: pentadecapeptide stopped being a problem at week 74
Reporting in. small win: pentadecapeptide stopped being a problem at week 74. Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live. Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads…
The evidence base, described honestly, which almost no summary of it does.
The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.
That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.
The evidence base, described honestly, which almost no summary of it does.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Do you have the mass spectrum?
the tendon claims are the most repeated and the least evidenced
the tendon claims are the most repeated and the least evidenced
Adding the standing caveat — research material is not approved for human use, wherever you are.